Patents Assigned to Tetralogic Pharmaceuticals Corporation
  • Publication number: 20100256046
    Abstract: Inhibitors of cIAP-1 and methods and compositions for treating proliferative disorders.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 7, 2010
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventors: Stacy SPRINGS, Mark McKINLAY, Sri CHUNDURU, Chris BENETATOS
  • Publication number: 20100143499
    Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.
    Type: Application
    Filed: July 24, 2007
    Publication date: June 10, 2010
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventor: Stephen M. Condon
  • Publication number: 20100144650
    Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.
    Type: Application
    Filed: July 24, 2007
    Publication date: June 10, 2010
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventor: Stephen M. Condon
  • Publication number: 20100113326
    Abstract: Compounds made up of a homodimer or heterodimer having monomeric units of formula (I): wherein: each A is, independently, NR1R2, or N+R1R2R3; each B is, independently, optionally substituted alkyl, alkenyl, or alkynyl, wherein one or more hydrogens are optionally replaced by fluorine; each U is, independently, CONH, C(O)O, C(S)O, C(S)NH, C(NH)NH, (CH2)1-5, or the inverse, thereof, wherein one or more carbons are optionally replaced by a heteroatom selected from O, S, and N; each V and W is, independently, (CH2)1-5, wherein one or more carbons are optionally replaced by C?O, C?S, or a heteroatom selected from O, S, and N, and one or more hydrogens are optionally replaced by a branched or unbranched alkyl or cycloalkyl, an optionally substituted aryl, arylalkyl, heteroaryl, heteroarylalkyl, OR4, SR4, or NR4R5; each X is, independently, optionally substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, wherein one or more carbons are optionally replaced by C?O, C?S, or a heteroatom selected from O, S, and N, a
    Type: Application
    Filed: July 24, 2007
    Publication date: May 6, 2010
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventor: Stephen M. Condon
  • Publication number: 20100075911
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 25, 2010
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPIN
  • Publication number: 20100056495
    Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.
    Type: Application
    Filed: July 24, 2007
    Publication date: March 4, 2010
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventor: Stephen M. Condon
  • Patent number: 7517906
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: April 14, 2009
    Assignee: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
  • Publication number: 20090048183
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
    Type: Application
    Filed: October 9, 2008
    Publication date: February 19, 2009
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
  • Patent number: 7456209
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: November 25, 2008
    Assignee: Tetralogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin